A Perfect Storm is Brewing Within the U.S. Healthcare Workforce: Public Policy, Data, and AI Will Help Us Weather It

Weathering the storm will require a bold, multi-pronged approach encompassing legislative action and a data-informed approach that leverages AI technology to plan, recruit, and realign more efficient care models.   The post A Perfect Storm is Brewing Within the U.S. Healthcare Workforce: Public Policy, Data, and AI Will Help Us Weather It appeared first on MedCity…

Read More

With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis

Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug. The post With FDA Approval for…

Read More